Retatrutide MASH and NAFLD — Sanyal 2024 Nature Medicine Liver Fat Data
Sanyal et al. 2024 in Nature Medicine published the MASH/NAFLD subgroup analysis of the Jastreboff retatrutide phase 2 trial — and the numbers are unprecedented. Liver fat measured by MRI-PDFF dropped 86% at the 12 mg arm over 48 weeks. Semaglutide and tirzepatide produce respectable liver-fat reductions in MASH trials; retatrutide's reductions are roughly twice as large at the high-dose arm. The reason is the glucagon-receptor agonism the older GLP-1 agents don't have. This is the research breakdown.
1. What MASH and NAFLD actually are
The nomenclature was updated in 2023:
- NAFLD (non-alcoholic fatty liver disease) → MASLD (metabolic dysfunction-associated steatotic liver disease)
- NASH (non-alcoholic steatohepatitis) → MASH (metabolic dysfunction-associated steatohepatitis)
The disease pipeline: hepatic fat accumulation → steatosis → inflammation → fibrosis → cirrhosis. The fat accumulation alone (MASLD/NAFLD) is the early end of the spectrum; MASH is the inflammatory progression with hepatocyte ballooning that can advance to fibrosis and structural liver damage.
Globally, MASLD prevalence sits at ~30% of adults — and MASH at roughly 5-7%. In the UAE specifically, the prevalence is meaningfully higher than the global average due to high diabetes and obesity rates; published Dubai cohort studies cite MASLD rates of 40%+ in metabolic-syndrome populations.
2. The Sanyal 2024 subgroup data
The 2023 Jastreboff retatrutide phase 2 obesity trial included MRI-PDFF (proton density fat fraction) measurement in participants with baseline hepatic steatosis. Sanyal et al. 2024 in Nature Medicine published the dedicated MASLD subgroup analysis. Key findings at 48 weeks:
| Arm | Baseline liver fat (MRI-PDFF) | 48-week liver fat | Relative reduction |
|---|---|---|---|
| Placebo | ~16-19% | ~14-17% | ~9-13% |
| Retatrutide 1 mg | ~17% | ~9% | ~42% |
| Retatrutide 4 mg | ~17% | ~7% | ~57% |
| Retatrutide 8 mg | ~17% | ~5% | ~71% |
| Retatrutide 12 mg | ~17% | ~2.5% | ~86% |
The clinical threshold for MRI-PDFF "normal liver fat" is <5%. The 8 mg and 12 mg arms moved the majority of participants from clinically meaningful steatosis to clinically normal liver fat content over 48 weeks.
3. The mechanistic case for glucagon agonism in liver
Retatrutide's distinguishing pharmacology is glucagon-receptor agonism alongside GLP-1 and GIP agonism. Glucagon's effect on the liver is direct and well-characterised in classical endocrinology:
- Increased hepatic fatty acid oxidation — glucagon signal upregulates the enzymes that burn fat for energy in the liver
- Increased lipolysis in adipose tissue — releases fatty acids into circulation, but the liver's enhanced oxidation prevents them from re-accumulating as hepatic fat
- Reduced hepatic de novo lipogenesis — fewer new fatty acids synthesised in the liver
- Increased energy expenditure — modest contribution but real
This is why retatrutide outperforms semaglutide and tirzepatide on liver fat specifically. Retatrutide adds a direct hepatic mechanism on top.
5. The hepatic enzyme tracking
For UAE researchers running liver-focused protocols, the lab-tracking framework:
- ALT, AST — baseline + every 4-8 weeks. Both should fall with reduced hepatic inflammation
- GGT — baseline + 8-12 week intervals. Sensitive to liver fat reduction
- Liver fibrosis-4 (FIB-4) score — composite marker (age + AST + ALT + platelets); useful for tracking advanced disease
- MRI-PDFF — gold standard quantitative imaging; expensive but specific. Available in Dubai's larger imaging centres.
- FibroScan (transient elastography) — non-invasive fibrosis measurement; useful adjunct, widely available in UAE.
6. The titration consideration for liver research
The Sanyal data shows the dose-response is clean — the 12 mg arm produces ~50% more relative liver-fat reduction than the 4 mg arm. Researchers prioritising liver endpoint should target the 8-12 mg maintenance dose rather than stopping at the 4 mg "weight-loss-effective" floor.
The full reconstitution math sits in our retatrutide reconstitution math writeup.
7. Co-administration considerations for liver research
Two adjuncts that researchers running liver-focused protocols sometimes layer:
- Tesamorelin. Stanley 2014 reported reduced liver fat (~21% relative reduction) in HIV lipodystrophy population alongside its visceral-fat effect. Mechanism: GH-driven increased hepatic lipid clearance. Adds a complementary mechanism to retatrutide's glucagon-driven one. Full context in GLP-1 muscle loss + Tesamorelin.
- NAD+. Some preclinical work supports NAD+ in hepatic steatosis (Gariani 2016) — research-grade interest in NAD+ as adjunct for liver health is growing. Mechanism: improved mitochondrial fatty-acid oxidation.
8. Phase 3 outlook
Eli Lilly initiated phase 3 retatrutide programs across multiple indications:
- TRIUMPH (obesity) — phase 3 in adult obesity, primary endpoint weight reduction at 88 weeks
- TRIUMPH-Outcomes (cardiovascular) — phase 3 cardiovascular outcomes
- Dedicated MASH phase 3 — anticipated based on Sanyal 2024 data; not yet enrolling at time of writing
FDA approval for any indication is anticipated 2027-2028. Until then, retatrutide remains a research compound — even after approval in obesity, MASH-indication approval will lag by years.
9. UAE-specific liver disease context
The UAE has substantially higher MASLD and MASH prevalence than the global average due to high diabetes (~17% adult prevalence) and obesity (~33%+) rates. Dubai-published cohort work cites MASLD prevalence in metabolic-syndrome populations of 40-55%. UAE liver clinics increasingly recognise MASH as a major contributor to advanced liver disease in middle-aged Emirati and expat populations.
The implication for the UAE peptide-research market: retatrutide demand has dual drivers — weight management AND liver health — that compound. Researchers running protocols often have both endpoints in mind.
10. UAE supply context
REVIVE LAB UAE supplies retatrutide in 5 mg and 10 mg HPLC-verified vials. The 10 mg vial is the more economical choice for researchers running the 8-12 mg maintenance protocol targeted at liver-fat reduction.
Retatrutide UAE ships same-day on Dubai orders before 4 PM, 24 hours nationwide, lot-level COA in every parcel.
11. The summary
- Mechanism: glucagon-receptor agonism drives direct hepatic fatty-acid oxidation; complementary to GLP-1 weight-loss-mediated indirect effect.
- Outperforms semaglutide (~33%) and tirzepatide (~62%) on direct comparison.
- Dose-response is clean — 12 mg > 8 mg > 4 mg arms for liver endpoint.
- Phase 3 MASH-dedicated trials anticipated; not yet licensed for any indication.
- UAE has higher-than-global MASLD prevalence; liver-fat endpoint is a major research-protocol driver in the local market.
References
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — subgroup analysis. Nat Med. 2024;30(7):2037-2048. PubMed
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PubMed
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310. PubMed
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist. Cell Metab. 2022;34(9):1234-1247. PubMed